At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
News|Podcasts|February 19, 2026
From Launch to Loss of Exclusivity: Reducing Access and Affordability Barriers Across the Brand Lifecycle
Author(s)CoverMyMeds
Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.
Advertisement
What you’ll learn:
- Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively.
- Learn how data-driven insights and affordability solutions can help biopharma support providers and pharmacists at every stage.
- Understand the strategic role of lifecycle planning in improving medication access, reducing industry fragmentation and enhancing patient outcomes.
Advertisement
Related to this article
Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.
At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.
At LogiPharma USA 2026, quality leaders explained why connected data, risk-based prioritization, and human accountability must come before AI in supply chain compliance.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
2
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
3
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
4
Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site
5